STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Z
Not yet recruiting
- CXCR4
- +2 more
- 68Ga-pentixafor
- PET/CT
- Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
2022-02-15
Feb 15, 2022T
Active, not recruiting
- Hematological Malignancies
- Tampere, FinlandTampere Univerisity Hospital
2021-09-30
Sep 30, 2021Z
Recruiting
- AML
- CD38 CAR T-cells
- Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
2022-02-13
Feb 13, 2022E
Recruiting
- Hematological Malignancies
- Thrombocytopenia
- EACA
- Platelet transfusion
- Atlanta, Georgia
- +1 more
2021-05-11
May 11, 2021N
Recruiting
- Hematological Malignancies
- Hematopoietic Stem Cell Transplantation
- PBSCs
- +2 more
- Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
2022-03-13
Mar 13, 2022K
Recruiting
- Hematological Malignancies
- Sacramento, California
- +2 more
2021-06-03
Jun 3, 2021G
Recruiting
- Hematological Malignancies
- omidubicel
- Los Angeles, California
- +5 more
2022-03-31
Mar 31, 2022S
Recruiting
- Hematological Neoplasms
- Recurrence
- Peg interferon alfa-2b
- Shanghai, Shanghai, ChinaShanghai Jiao Tong University Affilated First People's Hospital
2021-10-10
Oct 10, 2021Z
Recruiting
- Hematological Malignancies
- CAR-T cells
- Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
2021-03-08
Mar 8, 2021H
SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
Not yet recruiting
- Hematological Malignancy
- Lymphoma
- Canton, OhioGabrail Cancer Center Research, LLC
2022-03-14
Mar 14, 2022U
Recruiting
- MDS
- +2 more
- Brest, France
- +3 more
2021-08-16
Aug 16, 2021B
Active, not recruiting
- Myeloid Hematological Malignancies
- Busulfan
- +3 more
- Houston, TexasTexas Children's Hospital
2021-03-24
Mar 24, 2021Z
Recruiting
- AML
- CLL1 CAR T-cells
- Hangzhou, Zhejiang, China
- +1 more
2022-02-13
Feb 13, 2022C
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Ex-vivo expanded γδ T cell infusion
- Beijing, ChinaChinese PLA General Hospital
2022-03-24
Mar 24, 2022O
Active, not recruiting
- Immunogenicity
- +3 more
- Varese, Lombardia, ItalyUOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione M
2021-09-10
Sep 10, 2021C
Terminated
- Hematological Malignancies B
- additional biological samples
- Besançon, FranceCentre Hospitalier Régional Universitaire de Besançon
2021-01-29
Jan 29, 2021N
Recruiting
- Non Hodgkin Lymphoma
- +2 more
- Hefei, Anhui, China
- +2 more
2022-02-25
Feb 25, 2022I
Available
- Relapsed and Refractory Hematological Malignancies
- CAR-T cells
- Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
2021-02-09
Feb 9, 2021A
Completed
- Bloodstream Infection
- blood culture
- +3 more
- Assiut, EgyptAssiut university hospital
2022-02-15
Feb 15, 2022Z
Not yet recruiting
- Hematological Malignancies
- NK cells/Combined Monoclonal Antibodies
- Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
2020-12-08
Dec 8, 2020U
Recruiting
- Lymphoma and Acute Lymphoblastic Leukemia
- additional biological samples during CAR-T CELL treatment
- Montpellier, FranceDépartement d'hématologie clinique
2021-12-21
Dec 21, 2021A
Recruiting
- Solid Tumor
- Hematological Malignancy
- East Melbourne, Victoria, Australia
- +4 more
2021-11-04
Nov 4, 2021C
Not yet recruiting
- Advanced Solid Tumors and Hematological Malignancies
- TQB2928 Injection
- (no location specified)
2021-04-21
Apr 21, 2021A
Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells
Recruiting
- Hematological Malignancies
- +2 more
- T-reg depleted DLI
- Standard DLI
- Creteil, FranceHenri Mondor Hospital
2020-11-19
Nov 19, 2020Z
Not yet recruiting
- Infectious Diseases
- Hematological Malignancies
- LMP1 CAR T-cells
- Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
2020-12-05
Dec 5, 2020